Attention all Anglophiles: The newly named Wellcome Trust Sanger Institute, of Hinxton, UK, which is headed up by Allan Bradley, is looking for a few good scientists.
The Institute recently unveiled a five-year 300 million pound ($434 million) program that its parent, the Wellcome Trust, hopes will launch it to the forefront of post-genomic research.
Over the next five years, the institute will receive up to 36 million pounds ($52 million) to find and study genetic mutations that lead to common cancers, including breast, lung, colorectal, ovarian, and prostate cancer. The Cancer Genome Project, which has so far found some 80 abnormalities linked to cancer, is expected to lead to more information about tumor suppressor genes.
The Sanger Institute is also launching a new project to identify genes on the X chromosome that give rise to a variety of disorders. The project will use techniques from the Cancer Genome Project to look for genes involved in X-linked mental retardation.
Bradley, who took the helm at the Sanger Center in November 2000 after serving as Howard Hughes Medical Institute Investigator at Baylor College of Medicine in Houston, Texas, will spearhead the Institutes new initiative.
Outlining his vision, Bradley said "The new funding will allow the Wellcome Trust Sanger Institute to make a contribution to global science and medicine as significant as its contribution to the Human Genome Project. We will bring biology to the genome and translate the enormous amount of information encoded in our DNA into an understanding of gene function, providing the stimulus for real healthcare advances."
As part of the initiative, the institute will hire 20 new investigators, ranging from junior fellows to renowned principal investigators, and will establish postgraduate and postdoctoral programs to train future leaders in genomic science.
Additionally, the institute recently received funding for three postdoctoral fellows that will work to generate microarrays for the protozoan organism Dictyostelium discoideum. One position, based at the institute, will address the bioinformatics aspect of the project. Another position, based that the Medical Research Council (MRC) Laboratory of Molecular Biology, will focus on the biology of Dictyostelium.
For more information on positions available, contact Al Ivens, [email protected].
Alex Titomirov, co-founder of Bethesda, Md.-based InforMax, will leave his position as CEO of the company, which makes the Xpression NTI microarray expression analysis program, as soon as InforMax hires a new CEO.
Chief operating officer James Bernstein, also a co-founder, will retire at the end of the year, and will be replaced by John Green, currently executive vice president and chief financial officer.
The recruiting company Heidrick & Struggles has been hired to recruit the new chief executive, which the company hopes to do by the first quarter of 2002. Titomirov will remain chairman of the board of directors.